Quick Answer
MAXCYTE, INC. reported Diluted EPS of $0.42 per share (loss) for fiscal year 2025.
MAXCYTE, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.42 | -7.7% |
| 2024 | -$0.39 | -5.4% |
| 2023 | -$0.37 | -60.9% |
| 2022 | -$0.23 | -9.5% |
| 2021 | -$0.21 | -23.5% |
| 2020 | -$0.17 | +26.1% |
| 2019 | -$0.23 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | -9.1% | +0.0% |
| June 30, 2025 | -$0.12 | -33.3% | -9.1% |
| September 30, 2024 | -$0.11 | +0.0% | -22.2% |
| June 30, 2024 | -$0.09 | +10.0% | +18.2% |
| September 30, 2023 | -$0.11 | -83.3% | -10.0% |
| June 30, 2023 | -$0.10 | -25.0% | +9.1% |
| March 31, 2023 | -$0.11 | -175.0% | -83.3% |
| September 30, 2022 | -$0.06 | -100.0% | +25.0% |
- MAXCYTE, INC. showed a decrease of -7.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, MAXCYTE, INC.’s diluted eps has declined by 82.6% (from $0.23 per share (loss) to $0.42 per share (loss)).
- The most recent figure is from MAXCYTE, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: